ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-OR35

Daily Caffeine Consumption and Risk of AKI Related to Platinum-Salt Chemotherapy: A Prospective Cohort Study

Session Information

Category: Onco-Nephrology

  • 1500 Onco-Nephrology

Authors

  • Hamroun, Aghiles, Centre Hospitalier Regional Universitaire de Lille, Lille, Hauts-de-France, France
  • Antoine, Decaestecker, Centre Hospitalier Regional Universitaire de Lille, Lille, Hauts-de-France, France
  • Blum, David, Universite de Lille, Lille, Hauts-de-France, France
  • Cauffiez, Christelle, Universite de Lille, Lille, Hauts-de-France, France
  • Glowacki, François, Centre Hospitalier Regional Universitaire de Lille, Lille, Hauts-de-France, France
Background

Although their efficacy has been well-established in Oncology, the use of platinum salts remains limited due to the occurrence of acute kidney injury (AKI). Caffeine has been suggested as a potential pathophysiological actor of platinum salt-induced AKI, through its hemodynamic effects. This work aims to study the association between caffeine consumption and the risk of platinum salt-induced AKI.

Methods

We conducted a single-center prospective cohort study that has included 108 consecutive thoracic cancer patients receiving a first-line platinum-salt chemotherapy between January 2017 and December 2018. Before the first course of chemotherapy, they were all invited to fill in a previously validated auto-questionnaire, designed for a detailed evaluation of their daily caffeine consumption (mg/day). The association of daily caffeine consumption with the risk of platinum-salt induced AKI was estimated by cause-specific Cox proportional hazard model adjusted for several known confounders (baseline renal function and serum albumin level, nature and dose of platinum-salt, tobacco exposure, and Performans status).

Results

Overall, 34 patients (31.5%) (mean age 61.7 years, 65% men, 80% tobacco users) experienced a platinum salt-induced AKI (67% grade 1) and 47 (43.5%) died during follow-up (6.2 months [3.4; 8.4]). The group of high-caffeine consumption (≥ 386mg/day) had a twice higher risk of AKI (HR=2.12 [1.01; 4.45]) in the fully adjusted model. The cumulative incidence of AKI (considering the competing risk of death) was also significantly increased in the high-caffeine consumption group (p=0.03, see figure 1).

Conclusion

In a population of thoracic cancer patients, the group of high-caffeine consumption was exposed to a significantly higher risk of platinum salt-induced AKI.